Jump to content
Sign in to follow this  
Premi5

Galleri blood test

Recommended Posts

https://www.england.nhs.uk/2020/11/nhs-to-pilot-potentially-revolutionary-blood-test/

An innovative blood test that may spot more than 50 types of cancer will be piloted by the NHS in a world-leading programme, chief executive Sir Simon Stevens announced today.

The Galleri blood test, developed by GRAIL, can detect early stage cancers through a simple blood test, and will be piloted with 165,000 patients in a world-first deal struck by NHS England.

Research on patients with signs of cancer has already found that the test, which checks for molecular changes, can identify many types that are difficult to diagnose early, such as head and neck, ovarian, pancreatic, oesophageal and some blood cancers.

If the NHS programme shows the test also works as expected for people without symptoms it will be rolled out to become routinely available.

The test could help meet the NHS Long Term Plan goal of increasing the proportion of cancers caught early, which can be the key to reducing cancer mortality. Patients whose condition is diagnosed at ‘stage one’ typically have between five and 10 times the chance of surviving compared with those found at ‘stage four’.

NHS Chief Executive Sir Simon Stevens said: “While the good news is that cancer survival is now at a record high, over a thousand people every day are newly diagnosed with cancer. Early detection – particularly for hard-to-treat conditions like ovarian and pancreatic cancer – has the potential to save many lives. This promising blood test could therefore be a game-changer in cancer care, helping thousands more people to get successful treatment. This trial again confirms that the NHS is at the forefront of cutting edge treatments and technology.”

In England, around half of cancers are currently diagnosed at stage one or two but the NHS Long Term Plan is aiming to increase that to three quarters by 2028.

The GRAIL pilot, which is due to start in mid-2021, will involve 165,000 people.

That will include 140,000 participants aged 50 to 79 who have no symptoms but will have annual blood tests for three years.

People will be identified through NHS records and approached to take part. Anyone with a positive test will be referred for investigation in the NHS.

Another 25,000 people with possible cancer symptoms will also be offered testing to speed up their diagnosis after being referred to hospital in the normal way.

Results of these studies would be expected by 2023, and if outcomes are positive, then they would be expanded to involve around one million participants across 2024 and 2025.

Health and Social Care Secretary, Matt Hancock said: “We are building a world leading diagnostics industry in the UK – not just for coronavirus but for other diseases too. This exciting and ground-breaking new blood test from GRAIL will give us another tool to give more people the very best chance of survival, demonstrating how the UK continues to lead the way in using the latest innovative treatments to help patients.

“Many of us know a loved one who has battled against cancer and have seen first-hand the impact of this deadly disease.”

Professor Peter Johnson, National Clinical Director for Cancer at NHS England and improvement said: “The NHS has set itself an ambitious target, to find three-quarters of cancers at an early stage, when they have the highest chance of cure. Tests like this may help us get there far faster, and I am excited to see how this cutting-edge technology will work out, as we test it in clinics across the NHS.”

Sir Harpal Kumar, President of GRAIL Europe, said: “The Long Term Plan for cancer is one I’ve been immensely supportive of since it was published, and I applaud the NHS and  the government for setting out these ambitious goals and road map to diagnosing cancers earlier.

“Galleri, a simple blood test that’s capable of detecting more than 50 cancers, is a ground-breaking and potentially life-saving advance that could have a tremendous human and economic benefit. “Grail is thrilled to partner with the NHS and UK government to support the NHS Long Term Plan for earlier cancer diagnosis, and we are eager to bring our technology to patients in the UK as quickly as we can. I’m delighted we have the opportunity to work together to see if we can save many thousands more lives from cancer in the UK every year.”

Lord David Prior, Chair of NHS England said:  “Every year nearly 200,000 people in the UK die from cancer. Many of these people are diagnosed too late for treatment to be effective. This collaboration between the NHS and GRAIL offers the chance for a wide range of cancers to be diagnosed much earlier and could fundamentally change the outlook for people with cancer.”

The NHS has rolled out ‘Covid-friendly’ cancer treatments to keep patients safer during the pandemic in a £160 million initiative.

NHS patients were also the first in Europe to benefit from a full access deal on breakthrough CAR-T therapy for previously untreatable cancers.

NHS England has also recently done a deal to make a transformative treatment for cystic fibrosis, Kaftrio, available to thousands of patients.

 

@MisterrSingh

@jkvlondon

 

Be interested on your thoughts. Another 'game' being played by 'them'?

Also, 

Harpal Kumar

From Wikipedia, the free encyclopedia
 
 
 
Jump to navigationJump to search
Harpal Kumar
Harpal Kumar Z6Q6532 RT(1).jpg
 
Born 1965 (age 54–55)
Alma mater
Website www.cancerresearchuk.org/about-us/how-we-are-run/chief-executive-and-executive-board

Sir Harpal Singh Kumar (born 1965) is a British medical researcher who was the chief executive officer of Cancer Research UK[1][2][3] until June 2018,[4] when he left the charity to become Head of Johnson & Johnson Innovation EMEA.[5]

Early life and education[edit]

Kumar's parents were refugees. As Sikhs, they chose to leave what was to become Pakistan and move to India, where they ended up in refugee camps. Later they moved to England, where his father was employed sweeping factory floors, before eventually starting his own grocery store.[6]

Kumar attended Latymer Upper School, Hammersmith, and St. John's College, Cambridge, where he gained a Master of Engineering degree and a Master of Arts degree and won the Mobil Prize, Metal Box Prize, and Hughes Prize. He subsequently gained a Master of Business Administration degree with High Distinction as a Baker Scholar at Harvard Business School where he won the Ford Prize and the Wolfe Prize.[7][8]

Share this post


Link to post
Share on other sites

all I can say is how many billions they've collected over my lifetime 'to fight cancer/find the cure'  and still they are not any closer, most people are treated the same barbaric way cut, burn and poison  -  when they could all be told the truth of epigentics which says you can have the genes but they only trigger when the lifestyle is not right .

No one needs this test - imagine deluded ninnies chopping perfectly good organs out , body parts off at private prices because they've had the fear of Cancer put into them like that stupid woman Angelina Jolie . Genetics is only 30% of the equation not certainty.

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
Sign in to follow this  



  • Topics

  • Posts

    • On the topic of medicine and pharma take nasseau for example. Somebody could...   What Is Zofran? Zofran (ondansetron) is an antiemetic and selective 5-HT3 receptor antagonist prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery. Zofran is available in generic form. What Are Side Effects of Zofran? Common side effects of Zofran include: diarrhea, headache, fever, lightheadedness, dizziness, weakness, tiredness, drowsiness, constipation, rash, blurred vision, and muscle spasm. Dosage for Zofran Zofran adult dose is 32-mg given as a single dose or divided in three 0.15-mg/kg divided doses infused over 15 minutes. What Drugs, Substances, or Supplements Interact with Zofran? Zofran may interact with arsenic trioxide, tacrolimus, tramadol, antibiotics, antidepressants, anti-malaria medications, heart rhythm medicines, medicine to prevent or treat nausea and vomiting, medicines to treat psychiatric disorders, migraine headache medicines, narcotics, or seizure medications. Tell your doctor all medications and supplements you use. Zofran During Pregnancy and Breastfeeding Zofran should not be used during pregnancy unless the benefits outweigh the risks. It is not known if Zofran is excreted in breast milk. Consult your doctor before breastfeeding. Additional Information Our Zofran Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. What are the chances the less common side effects include death, stroke, seizure, anurism, or something horrible.  Or somebody could drink Bhang and kill two birds with one stoner and never encounter a negative side effect and especially not death.  And if we look at the meds this replaced I bet it's even worse. 
    • It's been pretty comprehensive. Sticking just to the topic no question. 
    • Basics of Sikhi made a video about that. The shabad was mistranslated.
    • Quick question: Didn't Guru Gobind Singh Ji say he wasn't Waheguru. Wondering if Guru Sahib meant that he wasn't solely Akalpurakh and how that would fit with the quotation above... Bhul Chuk Maaf 🙏
×
×
  • Create New...

Important Information

Terms of Use